243 related articles for article (PubMed ID: 29911959)
1. Conversion From Steroid to Everolimus in Maintenance Kidney Transplant Recipients With Posttransplant Diabetes Mellitus.
Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
Exp Clin Transplant; 2019 Feb; 17(1):47-51. PubMed ID: 29911959
[TBL] [Abstract][Full Text] [Related]
2. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
[TBL] [Abstract][Full Text] [Related]
3. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
[TBL] [Abstract][Full Text] [Related]
4. Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data.
Uchida J; Iwai T; Nishide S; Kabei K; Kuwabara N; Naganuma T; Kumada N; Takemoto Y; Nakatani T
Exp Clin Transplant; 2019 Apr; 17(2):190-195. PubMed ID: 30198840
[TBL] [Abstract][Full Text] [Related]
5. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
6. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
[TBL] [Abstract][Full Text] [Related]
7. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
Okabe Y; Noguchi H; Sato Y; Mei T; Kaku K; Ueki K; Tsuchimoto A; Nakamura M
Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
[TBL] [Abstract][Full Text] [Related]
9. Steroid avoidance or withdrawal for kidney transplant recipients.
Pascual J; Zamora J; Galeano C; Royuela A; Quereda C
Cochrane Database Syst Rev; 2009 Jan; (1):CD005632. PubMed ID: 19160257
[TBL] [Abstract][Full Text] [Related]
10. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism.
Uchida J; Kuwabara N; Machida Y; Iwai T; Naganuma T; Kumada N; Nakatani T
Transplant Proc; 2012 Jan; 44(1):128-33. PubMed ID: 22310596
[TBL] [Abstract][Full Text] [Related]
11. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
12. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
[TBL] [Abstract][Full Text] [Related]
13. Safety and metabolic advantages of steroid withdrawal after 6 months posttransplant in de novo kidney transplantation: A 1-year prospective cohort study.
Bang JB; Oh CK; Kim YS; Kim SH; Yu HC; Kim CD; Ju MK; So BJ; Lee SH; Han SY; Jung CW; Kim JK; Ahn HJ; Lee SH; Jeon JY
Immun Inflamm Dis; 2022 Mar; 10(3):e576. PubMed ID: 34913271
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
15. Replacement of mycophenolate acid with everolimus in patients who became neutropenic after renal transplant.
Savvidaki E; Kazakopoulos P; Papachristou E; Karavias D; Zavvos V; Voliotis G; Kalliakmani P; Marangos M; Goumenos DS
Exp Clin Transplant; 2014 Feb; 12(1):31-6. PubMed ID: 24471721
[TBL] [Abstract][Full Text] [Related]
16. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain.
Bilbao I; Salcedo M; Gómez MA; Jimenez C; Castroagudín J; Fabregat J; Almohalla C; Herrero I; Cuervas-Mons V; Otero A; Rubín A; Miras M; Rodrigo J; Serrano T; Crespo G; De la Mata M; Bustamante J; Gonzalez-Dieguez ML; Moreno A; Narvaez I; Guilera M;
Liver Transpl; 2015 Aug; 21(8):1056-65. PubMed ID: 25990257
[TBL] [Abstract][Full Text] [Related]
17. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
Tönshoff B; Tedesco-Silva H; Ettenger R; Christian M; Bjerre A; Dello Strologo L; Marks SD; Pape L; Veldandi U; Lopez P; Cousin M; Pandey P; Meier M
Am J Transplant; 2021 Jan; 21(1):123-137. PubMed ID: 32406111
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
[TBL] [Abstract][Full Text] [Related]
19. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients.
Santos T; Santos L; Macário F; Romãozinho C; Alves R; Campos M; Mota A
Transplant Proc; 2015 May; 47(4):906-10. PubMed ID: 26036483
[TBL] [Abstract][Full Text] [Related]
20. Steroid avoidance or withdrawal for kidney transplant recipients.
Haller MC; Royuela A; Nagler EV; Pascual J; Webster AC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD005632. PubMed ID: 27546100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
